Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy.
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
C D
CD
DiNardo
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
N
N
Daver
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
N
N
Jain
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
N
N
Pemmaraju
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
C
C
Bueso-Ramos
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
C C
CC
Yin
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
S
S
Pierce
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
E
E
Jabbour
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
J E
JE
Cortes
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
H M
HM
Kantarjian
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
G
G
Garcia-Manero
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
S
S
Verstovsek
D000368:Aged; D005260:Female; D006801:Humans; D053614:Janus Kinase 2 / Q000037:antagonists & inhibitors; D008297:Male; D008875:Middle Aged; D054437:Myelodysplastic-Myeloproliferative Diseases / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D011379:Prognosis
D053614:Janus Kinase 2